$2BStrategic acquisitionHealthcare & Life Sciences
Shionogi pays $2B for rare disease biotech IntraBio
Japan's Shionogi agreed to acquire Texas-based IntraBio for $2 billion, adding the marketed drug Aqneursa for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio reported sales of $68 million in 2025. The purchase follows Shionogi's acquisitions of Radicava and Tetra Therapeutics as it builds out a rare neurodegenerative disease franchise.
Why it matters: Shionogi is buying commercial-stage revenue rather than pipeline risk, a template Japanese pharma increasingly uses to expand in the U.S.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.